Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Jul 8;363(2):109-22.
doi: 10.1056/NEJMoa1000485. Epub 2010 Jun 30.

Adverse events associated with testosterone administration

Shehzad Basaria  1 , Andrea D Coviello, Thomas G Travison, Thomas W Storer, Wildon R Farwell, Alan M Jette, Richard Eder, Sharon Tennstedt, Jagadish Ulloor, Anqi Zhang, Karen Choong, Kishore M Lakshman, Norman A Mazer, Renee Miciek, Joanne Krasnoff, Ayan Elmi, Philip E Knapp, Brad Brooks, Erica Appleman, Sheetal Aggarwal, Geeta Bhasin, Leif Hede-Brierley, Ashmeet Bhatia, Lauren Collins, Nathan LeBrasseur, Louis D Fiore, Shalender Bhasin
Affiliations
Randomized Controlled Trial

Adverse events associated with testosterone administration

Shehzad Basaria et al. N Engl J Med. .

Abstract

Background: Testosterone supplementation has been shown to increase muscle mass and strength in healthy older men. The safety and efficacy of testosterone treatment in older men who have limitations in mobility have not been studied.

Methods: Community-dwelling men, 65 years of age or older, with limitations in mobility and a total serum testosterone level of 100 to 350 ng per deciliter (3.5 to 12.1 nmol per liter) or a free serum testosterone level of less than 50 pg per milliliter (173 pmol per liter) were randomly assigned to receive placebo gel or testosterone gel, to be applied daily for 6 months. Adverse events were categorized with the use of the Medical Dictionary for Regulatory Activities classification. The data and safety monitoring board recommended that the trial be discontinued early because there was a significantly higher rate of adverse cardiovascular events in the testosterone group than in the placebo group.

Results: A total of 209 men (mean age, 74 years) were enrolled at the time the trial was terminated. At baseline, there was a high prevalence of hypertension, diabetes, hyperlipidemia, and obesity among the participants. During the course of the study, the testosterone group had higher rates of cardiac, respiratory, and dermatologic events than did the placebo group. A total of 23 subjects in the testosterone group, as compared with 5 in the placebo group, had cardiovascular-related adverse events. The relative risk of a cardiovascular-related adverse event remained constant throughout the 6-month treatment period. As compared with the placebo group, the testosterone group had significantly greater improvements in leg-press and chest-press strength and in stair climbing while carrying a load.

Conclusions: In this population of older men with limitations in mobility and a high prevalence of chronic disease, the application of a testosterone gel was associated with an increased risk of cardiovascular adverse events. The small size of the trial and the unique population prevent broader inferences from being made about the safety of testosterone therapy. (ClinicalTrials.gov number, NCT00240981.)

PubMed Disclaimer

Conflict of interest statement

No other potential conflict of interest relevant to this article was reported.

Figures

Figure 1
Figure 1. Time-to-Event Analysis of Adverse Events, According to Body System
Kaplan–Meier estimates of the cumulative probability of incident cardiovascular-related adverse events (Panel A), events related to skin and subcutaneous tissue (Panel B), and events necessitating referral for medical evaluation (Panel C), from randomization to the end of the planned observation phase (9 months after randomization) are shown for the testosterone and placebo groups. The 95% confidence intervals are indicated by the shaded areas. The notches on the x axis show the distribution of censoring times before 9 months among participants in both groups. The P values were calculated from an unadjusted comparison of curves with the use of the log-rank test.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Newman AB, Simonsick EM, Naydeck BL, et al. Association of long-distance corridor walk performance with mortality, cardiovascular disease, mobility limitation, and disability. JAMA. 2006;295:2018–2026. - PubMed
    1. Guralnik JM, Ferrucci L, Simonsick EM, Salive ME, Wallace RB. Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. N Engl J Med. 1995;332:556–561. - PMC - PubMed
    1. von Bonsdorff M, Rantanen T, Laukkanen P, Suutama T, Heikkinen E. Mobility limitations and cognitive deficits as predictors of institutionalization among community-dwelling older people. Gerontology. 2006;52:359–365. - PubMed
    1. Metter EJ, Schrager M, Ferrucci L, Talbot LA. Evaluation of movement speed and reaction time as predictors of all-cause mortality in men. J Gerontol A Biol Sci Med Sci. 2005;60:840–846. - PubMed
    1. Ostchega Y, Harris TB, Hirsch R, Parsons VL, Kington R. The prevalence of functional limitations and disability in older persons in the US: data from the National Health and Nutrition Examination Survey III. J Am Geriatr Soc. 2000;48:1132–1135. - PubMed

Publication types

MeSH terms

Associated data